{"id":"NCT02741570","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","officialTitle":"An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-05","primaryCompletion":"2021-05-10","completion":"2022-09-22","firstPosted":"2016-04-18","resultsPosted":"2022-05-03","lastUpdate":"2023-09-21"},"enrollment":947,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Head and Neck Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","Opdivo"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["BMS-734016","Yervoy"]},{"type":"DRUG","name":"Cetuximab/Erbitux","otherNames":[]},{"type":"DRUG","name":"Cisplatin/Platinol","otherNames":[]},{"type":"DRUG","name":"Carboplatin/Paraplatin","otherNames":[]},{"type":"DRUG","name":"Fluorouracil/Adrucil","otherNames":[]}],"arms":[{"label":"Nivolumab and Ipilimumab","type":"EXPERIMENTAL"},{"label":"Extreme Regimen","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer","primaryOutcome":{"measure":"Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) â‰¥20","timeFrame":"From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)","effectByArm":[{"arm":"Nivolumab + Ipilimumab","deltaMin":17.58,"sd":null},{"arm":"EXTREME Regimen","deltaMin":14.59,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0469"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":133,"countries":["United States","Australia","Austria","Brazil","France","Germany","Greece","Ireland","Israel","Italy","Japan","Mexico","Poland","South Korea","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["36473143","33684371"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":313,"n":468},"commonTop":["Nausea","Anaemia","Fatigue","Rash","Constipation"]}}